NEW YORK (Reuters) Oct 09 - Pfizer Inc has halted patient enrollment in a late-stage lung cancer trial of its experimental drug, figitumumab, for safety reasons, the drugmaker said on Friday.
The halt was recommended by independent safety monitors overseeing the study. In their review, the monitors found more serious adverse events, including deaths, with patients receiving figitumumab, the company said.
Pfizer said currently enrolled patients may continue their treatment in consultation with their physicians. As of Sept 30, 681 patients were enrolled in the phase 3 study out of a target of 820, a company spokesman said.
The company said it notified all clinical trial investigators and regulatory agencies and will work closely with the safety monitoring committee on analyzing the data before issuing further guidance.
The enrollment halt is a blow for Pfizer, which is seeking new medicines as many of its top sellers face patent expirations.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου